Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-009759
Filing Date
2017-05-09
Accepted
2017-05-09 14:27:10
Documents
58
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q insy-10q_20170331.htm 10-Q 1888429
2 EX-31.1 insy-ex311_8.htm EX-31.1 9119
3 EX-31.2 insy-ex312_7.htm EX-31.2 9003
4 EX-32 insy-ex32_6.htm EX-32 9107
  Complete submission text file 0001564590-17-009759.txt   7609589

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT insy-20170331.xml EX-101.INS 2050812
6 XBRL TAXONOMY EXTENSION SCHEMA insy-20170331.xsd EX-101.SCH 39625
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE insy-20170331_cal.xml EX-101.CAL 50612
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE insy-20170331_def.xml EX-101.DEF 111666
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE insy-20170331_lab.xml EX-101.LAB 327993
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE insy-20170331_pre.xml EX-101.PRE 248502
Mailing Address 10220 SOUTH 51ST STREET SUITE 2 PHOENIX AZ 85044
Business Address 10220 SOUTH 51ST STREET SUITE 2 PHOENIX AZ 85044 602-910-2617
Insys Therapeutics, Inc. (Filer) CIK: 0001516479 (see all company filings)

EIN.: 510327886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35902 | Film No.: 17825856
SIC: 2834 Pharmaceutical Preparations